Trial Profile
A 7-month multicenter, parallel, double-blind, placebo-controlled comparison of 150-300mg/day of extended-release bupropion hydrochloride and placebo for the prevention of seasonal depressive episodes in subjects with a history of seasonal affective disorder followed by an 8-week observational follow-up phase
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Bupropion (Primary)
- Indications Seasonal affective disorder
- Focus Therapeutic Use
- Acronyms SAD
- Sponsors GSK
- 12 Oct 2005 New trial record.